Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AIT Therapeutics, Inc. (OTC: AITB).

Full DD Report for AITB

You must become a subscriber to view this report.


Recent News from (OTC: AITB)

AIT Therapeutics Announces $526,500 Sale of Common Stock To Institutional Investor, Lincoln Park Capital Fund
GARDEN CITY, N.Y. and REHOVOT, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB:AITB) (“AIT Therapeutics or the “Company”), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the trea...
Source: GlobeNewswire
Date: September, 05 2018 08:00
AIT Therapeutics to Present Nitric Oxide Data at Two Upcoming Scientific Conferences
Highlights at European Respiratory Society (ERS) to include updated data from company’s NO-BRO Pilot study of high-dose inhaled nitric oxide (NO) in infants hospitalized with acute bronchiolitis                Additional pre-clinical data ...
Source: GlobeNewswire
Date: September, 04 2018 08:00
AIT Therapeutics reports Q1 results
AIT Therapeutics ( OTCQB:AITB ): Q1 EPS of -$0.36 More news on: AIT Therapeutics, Inc., Earnings news and commentary, Tech stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 14 2018 08:12
AIT Therapeutics Reports Financial Results for First Fiscal Quarter 2019
Started commercial development of ventilator compatible NO generator and delivery system -- FDA 510(k) submission expected in the first quarter of calendar 2019 Human and in-vitro Nitric Oxide (NO) data presented at the 3rd Annual World Bronchiectasis Conference Bill Forbes, forme...
Source: GlobeNewswire
Date: August, 14 2018 08:00
AIT Therapeutics Announces $20 Million Common Stock Purchase Agreement with Institutional Investor, Lincoln Park Capital Fund
GARDEN CITY, N.Y., and REHOVOT, Israel, Aug. 13, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB) (“AIT Therapeutics or the “Company”),  a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the ...
Source: GlobeNewswire
Date: August, 13 2018 08:30
AIT Therapeutics Schedules Fiscal First Quarter 2019 Financial Results Conference Call and Webcast
Call scheduled for Tuesday, August 14  at 10:30am Eastern Time. NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients...
Source: GlobeNewswire
Date: August, 01 2018 16:15
AIT Therapeutics Announces Start of Manufacturing of Ventilator Compatible NO Generator and Delivery System
FDA 510(k) submission expected in the first quarter of calendar 2019 Sparton's Watertown facility to provide manufacturing services GARDEN CITY, N.Y. and REHOVOT, Israel, July 30, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and biopha...
Source: GlobeNewswire
Date: July, 30 2018 08:30
AIT Therapeutics Announces Human and In-Vitro Nitric Oxide (NO) Data Presented at the 3rd Annual World Bronchiectasis Conference
Presentations highlighted the direct killing effect of NO on Mycobacterium abscessus (M. abscessus) and Pseudomonas aeruginosa (P. aeruginosa) as well as the use of the NO generator and delivery system as a potential therapy for M. abscessus complex (MABSC) lung infection GARDEN CITY, N...
Source: GlobeNewswire
Date: July, 16 2018 08:30
AIT Therapeutics Announces Human and In-Vitro Nitric Oxide Data to be Presented at the 3rd Annual World Bronchiectasis Conference
Two presentations to highlight the direct killing effect of nitric oxide and the use of the nitric oxide generator and delivery system as a potential therapy for Mycobacterium abscessus complex (MABSC) lung infection NEW YORK, June 27, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (O...
Source: GlobeNewswire
Date: June, 27 2018 16:30
AIT Therapeutics Reports Financial Results for Three Months Ended March 31, 2018
Announced positive top-line data for Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study Presented data from its inhaled Nitric Oxide study in patients infected with mycobacterium abscessus complex (MABSC) at the 2018 American Thoracic Society Conference Strengthened IP with new pa...
Source: GlobeNewswire
Date: June, 14 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A4.05N/AN/A0
2018-12-134.054.054.054.05100
2018-12-124.104.044.154.044,950
2018-12-11N/A4.10N/AN/A0
2018-12-104.214.104.214.091,550

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-122,5004,95050.5051Short
2018-12-101,0001,55064.5161Short
2018-12-063004,7456.3224Cover
2018-12-0440080050.0000Short
2018-12-036,75010,32565.3753Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AITB.


About AIT Therapeutics, Inc. (OTC: AITB)

Logo for AIT Therapeutics, Inc. (OTC: AITB)

Not available

 

Contact Information

 

 

Current Management

  • Steven A. Lisi / CEO
  • Amir Avniel / President, COO
  • Hai Aviv / CFO
    • Mr. Aviv, who is years old, will join the Company from Babylon Ltd., a publiclytraded Israeli company listed on the Tel Aviv Stock Exchange, operating in the fields of Internet, risk capital investments and software, where he has served as Chief Financial Officer from to the present. From to , Mr. Aviv served as Babylon s corporate controller. Mr. Aviv is a certified public accountant and, from to , served as manager at the Ernst amp Young Accounting Firm, Kost Forer, Gabbay amp Kasierer, working predominantly with the hightech team.
  • Amir Avniel /
  • Steven A. Lisi /

Current Share Structure

  • Market Cap: $18,230,789 - 03/20/2018
  • Issue and Outstanding: 6,097,254 - 11/01/2017

 


Recent Filings from (OTC: AITB)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Amendment to general form for registration of securities under the Securities Act of 1933
Filing Type: S-1/AFiling Source: edgar
Filing Date: May, 07 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 07 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 02 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 30 2018
Amendment to general form for registration of securities under the Securities Act of 1933
Filing Type: S-1/AFiling Source: edgar
Filing Date: March, 29 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: March, 28 2018

 

 


Daily Technical Chart for (OTC: AITB)

Daily Technical Chart for (OTC: AITB)


Stay tuned for daily updates and more on (OTC: AITB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AITB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AITB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AITB and does not buy, sell, or trade any shares of AITB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/